首页> 外文期刊>Chemotherapy Research and Practice >Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
【24h】

Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer

机译:Nedaplatin:宫颈癌患者的放射增敏剂

获取原文
           

摘要

Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary. Nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed with the aim of producing a treatment with a similar effectiveness to cisplatin but decreased renal and gastrointestinal toxicities. Based on the promising results of preclinical studies, the clinical efficacy of nedaplatin as a radiosensitizing agent was evaluated in patients with cervical cancer. Retrospective analysis of nedaplatin-based concurrent chemoradiotherapy (CCRT) against cervical cancer suggested that nedaplatin-based CCRT can be considered as an alternative to cisplatin-based CCRT in both early-stage and advanced-stage cervical cancer patients. However, due to the lack of a randomized controlled study, nedaplatin-based CCRT has not been convincingly proven to be clinically effective in patients with cervical cancer. Further investigations in randomized controlled trials are therefore needed.
机译:尽管使用基于顺铂的同时放化疗在宫颈癌的治疗方面取得了最新进展,但是仍然出现了实质性的治疗失败,特别是在具有高风险预后因素的晚期患者和早期宫颈癌患者中。因此,有必要进一步提高这些患者的生存率和生活质量。研发了顺铂的衍生物奈达铂(顺式-二氨-糖铂),其目的是产生一种与顺铂相似的药效,但降低了肾脏和胃肠道毒性。基于临床前研究的有希望的结果,评估了奈达铂作为放射增敏剂在宫颈癌患者中的临床疗效。对基于尼达铂的同时放化疗治疗宫颈癌的回顾性分析表明,在早期和晚期宫颈癌患者中,基于尼达铂的CCRT均可被视为基于顺铂的CCRT的替代方案。然而,由于缺乏随机对照研究,基于奈达铂的CCRT尚未令人信服地证明在宫颈癌患者中具有临床疗效。因此,需要在随机对照试验中进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号